Stoke Therapeutics, Inc. (STOK) — closed signal from October 5, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 3, 2026.
Predicted vs. what happened
What happened
Reached its target in 9 days.
The thesis — published October 5, 2025
Stoke looks like a leading biotech name with steady upward momentum. The recent average price is climbing, and normal trading activity helped balance a short-lived dip in momentum, which fits a buy-on-dips approach. Fresh mentions of industry highs and leadership updates keep interest strong. Over the next 0-3 months, higher prices are more likely if pullbacks stay shallow. News swings and sharp moves remain the main risks, so keep positions flexible.
Primary drivers
- Positive sentiment and a steady rise in the recent average price
- Biotech strength plus updates on its drug pipeline keep interest high
- Chart and business both look solid, lowering chances of big surprises
- Investor demand for the sector makes small-dip buying more likely to work
How it played out
STOK: target reached in 9 days
Lyra published STOK at $25.56 on 2025-10-05 with 32% expected growth and a $33.74 target. The thesis pointed to positive sentiment, a steady rise in the recent average price, biotech strength, drug pipeline updates, a solid chart and business, and investor demand for the sector.
Inside the window, STOK reached the target in 9 days. It peaked at $38.69 on 2025-10-16, with a 51.4% gain, then ended the window at $30.90 on 2026-01-03. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.